Cancer systems immunology is a highly interdisciplinary field that is advancing our ability to understand and predict the complex behavior that orchestrates the interplay between tumors and the immune system.

Infrared high-pulse-energy low-pulse-repetition-rate excitation advances deep intravital microscopy in strongly scattering tissues such as skin tumors and thick bone, thereby bringing previously inaccessible tumor areas in reach with subcellular resolution.

A comprehensive literature review delineates the current knowledge of how systemic context, such as age and obesity, can impact CD8⁺ T cell function, anti-tumor immunity, and immunotherapy responsiveness.

Tumor stiffness blocks T cell migration in tumors.

Downregulation of mitochondrial activity by immunosuppressive tumor-derived soluble factors leads to systemic unresponsiveness to the PD-1 blockade therapy.

Single-cell sequencing and functional analysis identify T cells that can be useful for marker selection and cell therapy in uveal melanoma, a disease largely unresponsive to conventional immune checkpoint therapies.

Mucosal-associated invariant T cells, an emerging member of the innate-like T cells abundant in humans bridging the innate and the adaptive immunity, could be exploited as a novel tool for cancer immunotherapy through cell reprogramming.

ImmunoCluster permits nonspecialist users to interrogate liquid and imaging mass, and flow cytometry datasets, resolving novel layers of cellular heterogeneity and insight, as well as producing publishable outputs and figures.

Tumor-infiltrating regulatory T cells are regulated by the immunoreceptor CD300a, which suppresses signals from tumor-derived extracellular vesicles.

Why does cancer develop in situations where the immune system is perfectly capable of eliminating it?